Compare Neurocrine Biosciences Inc (NBIX) vs Vertiv Holdings Co (VRT) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Neurocrine Biosciences Inc vs Vertiv Holdings Co — how do they compare? Neurocrine Biosciences Inc trades at $179 (market cap $17.40B), while Vertiv Holdings Co trades at $307.03 (market cap $112.03B). The key difference: Vertiv Holdings Co is far larger — about 6.4× Neurocrine Biosciences Inc's market cap, and Vertiv Holdings Co pays a 0.09% dividend while Neurocrine Biosciences Inc pays none. Which is the better fit depends on your goals.
| NBIX | VRT | |
|---|---|---|
Market Cap | $17.40B | $112.03B |
Sector | Health | Technology |
52-Week High | $180.55 | $376.23 |
52-Week Low | $123.10 | $121.82 |
Enterprise Value | $16.49B | $112.80B |
Dividend Yield | — | 0.09% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
Vertiv (VRT) trades at $291.67, up 0.73% today, with a bearish technical signal but strong fundamental momentum. The stock has consistently beaten earnings estimates in recent quarters, with Q2 2026 results expected on July 29, 2026. Revenue and net income are projected to grow in 2026, supported by robust demand for AI data center infrastructure, including recent expansions in cooling solutions manufacturing.
The outlook is positive due to AI-driven growth and a $15 billion order backlog, though high valuation multiples and technical weakness pose risks. Analyst consensus is strongly bullish with a $402.92 price target, but investors should monitor execution on growth targets and competitive pressures in the data center equipment market.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Neurocrine Biosciences Inc
Neurocrine Biosciences, Inc. is a biopharmaceutical company focused on discovering, developing, and commercializing innovative treatments for neurological, endocrine, and psychiatric disorders. The company's portfolio targets conditions such as tardive dyskinesia, endometriosis, and Parkinson's disease. NBIX leverages its expertise in neurobiology and small-molecule drug development to address diseases with significant unmet medical needs.
Read more on NBIX →About Vertiv Holdings Co
Vertiv is a global leader in critical digital infrastructure, providing essential power, cooling, and IT management solutions for data centers, communication networks, and industrial facilities. As the primary provider of advanced thermal management and liquid cooling systems, Vertiv is a central player in the AI revolution, enabling the extreme density and power requirements of next-generation GPU-driven computing.
Read more on VRT →
